Skip to content

Study on the efficacy, safety and postoperative cognitive dysfunction of continuous infusion of remimazolam toluesulfonate in PFNA surgery for elderly patients

Study on the efficacy, safety and postoperative cognitive dysfunction of continuous infusion of remimazolam toluesulfonate in PFNA surgery for elderly patients

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500106656
Enrollment
Unknown
Registered
2025-07-28
Start date
2025-04-14
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intertrochanteric fractures of the femur in elderly patients

Interventions

Experimental group (remimazolam tosilate group) :The experimental group was continuously infused with remimazolam tosilate for anesthesia maintenance.
Control group (propofol group):The control group was continuously infused with propofol for intraoperative anesthesia maintenance.

Sponsors

The Fourth People's Hospital of Zigong City
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.All patients meet the indication criteria for surgical anesthesia. 2.Age > 65 years old, ASA II - III grade. 3.Agree to this clinical trial and sign the informed consent form. 4.The experimental research is approved by the hospital ethics committee.

Exclusion criteria

Exclusion criteria: 1.Patients who cannot tolerate surgical trauma; 2.Patients allergic to remimazolam tosylate; 3.Patients with multiple diseases or accompanied by failure of vital organs; 4.Patients with mental illness or cognitive impairment; 5.Patients who refuse to participate in this clinical trial.

Design outcomes

Primary

MeasureTime frame
Blood pressure;

Secondary

MeasureTime frame
Mini - Cognitive Function Scale Score;Interleukin-6;C-reactive protein;

Countries

China

Contacts

Public ContactHou Ping

The Fourth People's Hospital of Zigong City

1414675375@qq.com+86 138 9008 5343

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026